SBIR-STTR Award

Validation of a Novel Nf-Kb Inhibitor in Inflammatory Bowel Disease
Award last edited on: 4/19/19

Sponsored Program
STTR
Awarding Agency
NIH : NIDDK
Total Award Amount
$1,613,206
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
Scott E Plevy

Company Information

Theralogics Inc

1829 East Franklin Street
Chapel Hill, NC 27514
   (919) 969-6659
   N/A
   www.theralogics.com,www.theralogix.com

Research Institution

University of North Carolina

Phase I

Contract Number: 1R41DK074193-01
Start Date: 9/15/06    Completed: 8/31/07
Phase I year
2006
Phase I Amount
$216,950
The human inflammatory bowel diseases (IBDs), Crohn's disease (CD) and ulcerative colitis (UC), affect over one million Americans. Until recently, therapies for these disorders have non-specifically suppressed the immune response to inhibit intestinal inflammation. Specific understanding of immune pathways has led to the development of TNF blockade as a treatment for CD and possibly UC. However, this biological intervention is only effective in a minority of patients, and is associated with short and long term toxicities. Therefore, significant unmet medical needs exist in these debilitating human diseases. A preponderance of experimental results highlights the importance of the NF-KB family of transcription factors in the initiation and perpetuation of chronic inflammation in IBD. The purpose of this Phase I STTR is to provide preclinical efficacy and mechanistic data to support the development of a novel cell permeable NF-KB inhibitory peptide for the treatment of IBD. Investigators at the applicant organization, TheraLogics, Inc., have been at the forefront of NF-KB research and hold an intellectual property position on the NF-KB inhibitor. This inhibitor to be developed is a short peptide comprised of an 8 lysine protein transduction domain (PTD) with an IKB kinase (IKK) inhibitory sequence, "NF-KB essential modulator" (NEMO) binding domain (NBD) (collectively referred to as PTD-NBD). Compared to other NF-KB inhibitors in development for chronic inflammatory diseases, PTD-NBD has the advantages of: (i) inhibiting activated NF-KB, a hallmark of chronic inflammation, (ii) not inhibiting basal NF-KB activity which may be involved in fundamental cellular processes distinct from inflammation, (iii) having pharmacodynamic effects which outlast its pharmacokinetic properties, and (iv) the potential for systemic and local delivery. The collaboration with the University of Pittsburgh combines investigators with expertise in and intellectual property for the delivery of cell permeable peptides in inflammatory diseases with a leading group in basic and clinical IBD research. Experiments in this proposal will provide the preclinical and pharmacodynamic data to support the development of PTD-NBD in later phase studies as a potential therapy for human IBD. Relevance of this research to public health: The human IBDs, CD and UC, affect over one million Americans. There are many pressing, unmet medical needs to develop safer and more effective treatments for these lifelong, debilitating illnesses. In this application, investigators at TheraLogics, Inc., and the University of Pittsburgh propose to test a new treatment in mouse models of IBD that can potentially be administered by mouth and works by turning off a protein, NF-KB, which is a "master switch" that turns on inflammation in the intestine. If these studies are successful, future studies will be designed to assess the safety of this new compound, and rapidly develop this treatment to evaluate in people with IBD.

Thesaurus Terms:
I Kappa B Beta, Antiinflammatory Agent, Drug Screening /Evaluation, Gastrointestinal Disorder Chemotherapy, Gastrointestinal Pharmacology, Inflammatory Bowel Disease, Kinase Inhibitor, Nonhuman Therapy Evaluation, Nuclear Factor Kappa Beta, Peptide Analog Crohn's Disease, T Cell Receptor, Binding Protein, Disease /Disorder Model, Enzyme Activity, Gene Expression, Helper T Lymphocyte, Interleukin 10, Intestinal Mucosa, Intraperitoneal Injection, Lysine, Myeloperoxidase, Oral Administration, Ulcerative Colitis Histopathology, Laboratory Mouse

Phase II

Contract Number: 2R42DK074193-02A1
Start Date: 9/15/06    Completed: 7/31/14
Phase II year
2012
(last award dollars: 2013)
Phase II Amount
$1,396,256

The human inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis, affect over one million Americans and significant unmet medical needs still exist. Activation of NF??B transcription factors are central events in the initiation and perpetuation of chronic inflammation in IBD. TheraLogics, Inc., have been at the forefront of NF??B research and hold intellectual property pertaining to novel NF??B inhibitor peptides including TLX1423. TLX1423 is a peptide comprised of a 8 lysine (8K) protein transduction domain (PTD) with an I?B kinase (IKK) inhibitory sequence, ""NF??B essential modulator"" (NEMO) binding domain (NBD). Compared to other NF??B inhibitors, TLX1423 has the advantages of inhibiting activated NF??B, a hallmark of chronic inflammation, but not inhibiting basal NF??B activity, involved in fundamental cellular processes thus correlating with toxicity. During phase 1, we achieved important milestones in the development of TLX1423 as a therapy for IBD and published these findings in the Journal of Immunology. We demonstrated transduction of TLX1423 into cells and tissues. In-vivo, TLX1423 inhibited LPS-activated NF??B in the ileum, but did not inhibit basal NF??B in Peyer's patches. IL-10-/- mice treated systemically with TLX1423 demonstrated amelioration of established colitis and decreased NF??B activation in the lamina propria. In phase 1, we also demonstrated that intrarectal administration of TLX1423 results in amelioration of intestinal inflammation in two experimental IBD models. The ideal therapeutic agent to treat IBD would be administered by mouth. However, drug delivery to the inflamed intestine remains a challenge for two main reasons: 1) lack of highly effective immunomodulatory agents that can be delivered locally and inhibit their targets in intestinal immune cells and, 2) lack of vehicles to carry these agents to the site of inflammation with minimal degradation in the GI tract. The multidisciplinary team assembled for this phase 2 proposal has developed innovative solutions to these hurdles. This would be an important advancement to minimize toxicity, increase patient compliance, and improve quality of life. To address these challenges, we have developed microemulsion (ME)- based delivery systems suitable for local administration of TLX1423, and via enteric release strategies, target the peptide to inflamed regions of the GI tract. We show preliminary data that PTD peptides in water-in-oil (w/o) MEs are efficiently delivered to the large intestine in mice as compared to free PTD peptides. TheraLogics has enlisted CMC, regulatory and clinical consultants to translate results of this phase 2 program into the next phases, including GMP manufacturing, GLP safety/toxicity studies, and an IND submission.

Public Health Relevance:
This is an STTR application representing an industry-academic collaboration between TheraLogics, Inc., the University of North Carolina at Chapel Hill, and the North Carolina State School of Veterinary Medicine. The applicant organization is TheraLogics, Inc., a small North Carolina based biotechnology company. The Principal Investigator on this application is Scott E. Plevy in the University of North Carolina School of Medicine. The purpose of this application is to develop a novel NF??B inhibitor for the treatment of inflammatory bowel disease. The investigators have already been successful in demonstrating efficacy of the NF??B inhibitor in experimental models of colitis. This application will further develop this inhibitor for oral delivery and further test this molecule in small and lrge animals. It is our hope that the work performed in this application will lead to clinical development in humans in the next phase.